A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases

Yanina Jansen, Vibeke Krüse, Jurgen Corthals, Kelly Schats, Pieter‐Jan van Dam, Teofila Seremet, Carlo Heirman, Liève Brochez, Mark Kockx, Kris Thielemans, Bart Neyns